Metabolic compensation of fitness costs is a general outcome for antibiotic- resistant Pseudomonas aeruginosa mutants overexpressing efflux pumps

mBio

Volumn 8, Issue 4, 2017, Pages

  Pacheco, Jorge Olivares ^a,b   Alvarez Ortega, Carolina ^a,c   Rico, Manuel Alcalde ^a   Martínez, José Luis ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE VALPARAÍSO   (Chile)

^c Bacmine SL   (Spain)

Author keywords

Antibiotic resistance; Efflux pumps; Fitness costs; Pseudomonas aeruginosa

Indexed keywords

ACIDIFICATION; ANAEROBIC CAPACITY; ANAEROBIC REACTOR; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFUSION; FITNESS; GROWTH RATE; HOMEOSTASIS; METABOLIC CAPACITY; METABOLIC COMPENSATION OF FITNESS COST; MICROBIOLOGICAL PARAMETERS; NONHUMAN; OUTCOME ASSESSMENT; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; DRUG EFFECTS; ELECTRON TRANSPORT; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; MUTATION; PHYSIOLOGY; REPRODUCTIVE FITNESS;

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CARRIER PROTEIN; MEMBRANE PROTEIN; MEXA PROTEIN, PSEUDOMONAS AERUGINOSA; MEXB PROTEIN, PSEUDOMONAS AERUGINOSA; MEXC PROTEIN, PSEUDOMONAS AERUGINOSA; MEXD PROTEIN, PSEUDOMONAS AERUGINOSA; NITRIC ACID DERIVATIVE; OUTER MEMBRANE PROTEIN;

ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ELECTRON TRANSPORT; GENETIC FITNESS; MEMBRANE PROTEINS; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MUTATION; NITRATES; PSEUDOMONAS AERUGINOSA;

EID: 85029073607     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00500-17     Document Type: Article

References (65)

1. Andersson DI, Levin BR. 1999. The biological cost of antibiotic resistance. Curr Opin Microbiol 2:489-493. https://doi.org/10.1016/S1369-5274(99)00005-3.
2. Andersson DI. 2006. The biological cost of mutational antibiotic resistance: any practical conclusions? Curr Opin Microbiol 9:461-465. https://doi.org/10.1016/j.mib.2006.07.002.
3. Sundqvist M, Geli P, Andersson DI, Sjölund-Karlsson M, Runehagen A, Cars H, Abelson-Storby K, Cars O, Kahlmeter G. 2010. Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. J Antimicrob Chemother 65:350-360. https://doi.org/10.1093/jac/dkp387.
4. Kollef MH. 2006. Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? Clin Infect Dis 43(Suppl 2):S82-S88. https://doi.org/10.1086/504484.
5. Kollef MH. 2001. Is there a role for antibiotic cycling in the intensive care unit? Crit Care Med 29:N135-N142. https://doi.org/10.1097/00003246-200104001-00014.
6. Bottger EC, Pletschette M, Andersson D. 2005. Drug resistance and fitness in Mycobacterium tuberculosis infection. J Infect Dis 191:823-824. https://doi.org/10.1086/427517.
7. Balsalobre L, de la Campa AG. 2008. Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes. Antimicrob Agents Chemother 52:822-830. https://doi.org/10.1128/AAC.00731-07.
8. Sánchez MB, Martinez JL. 2012. Differential epigenetic compatibility of qnr antibiotic resistance determinants with the chromosome of Escherichia coli. PLoS One 7:e35149. https://doi.org/10.1371/journal.pone.0035149.
9. Björkman J, Nagaev I, Berg OG, Hughes D, Andersson DI. 2000. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287:1479-1482. https://doi.org/10.1126/science.287.5457.1479.
10. Zorzet A, Andersen JM, Nilsson AI, Møller NF, Andersson DI. 2012. Compensatory mutations in agrC partly restore fitness in vitro to peptide deformylase inhibitor-resistant Staphylococcus aureus. J Antimicrob Chemother 67:1835-1842. https://doi.org/10.1093/jac/dks168.
11. Lind PA, Tobin C, Berg OG, Kurland CG, Andersson DI. 2010. Compensatory gene amplification restores fitness after inter-species gene replacements. Mol Microbiol 75:1078-1089. https://doi.org/10.1111/j.1365-2958.2009.07030.x.
12. Löfmark S, Jernberg C, Billström H, Andersson DI, Edlund C. 2008. Restored fitness leads to long-term persistence of resistant Bacteroides strains in the human intestine. Anaerobe 14:157-160. https://doi.org/10.1016/j.anaerobe.2008.02.003.
13. Paulander W, Maisnier-Patin S, Andersson DI. 2007. Multiple mechanisms to ameliorate the fitness burden of mupirocin resistance in Salmonella typhimurium. Mol Microbiol 64:1038-1048. https://doi.org/10.1111/j.1365-2958.2007.05713.x.
14. Kugelberg E, Löfmark S, Wretlind B, Andersson DI. 2005. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. J Antimicrob Chemother 55:22-30. https://doi.org/10.1093/jac/dkh505.
15. Olivares J, Alvarez-Ortega C, Martinez JL. 2014. Metabolic compensation of fitness costs associated with overexpression of the multidrug efflux pump MexEF-OprN in Pseudomonas aeruginosa. Antimicrob Agents Chemother 58:3904-3913. https://doi.org/10.1128/AAC.00121-14.
16. Freihofer P, Akbergenov R, Teo Y, Juskeviciene R, Andersson DI, Bottger EC. 2016. Nonmutational compensation of the fitness cost of antibiotic resistance in mycobacteria by overexpression of tlyA rRNA methylase. RNA 22:1836-1843. https://doi.org/10.1261/rna.057257.116.
17. Martínez JL, Baquero F, Andersson DI. 2007. Predicting antibiotic resistance. Nat Rev Microbiol 5:958-965. https://doi.org/10.1038/nrmicro1796.
18. Martínez JL, Coque TM, Baquero F. 2015. What is a resistance gene? Ranking risk in resistomes. Nat Rev Microbiol 13:116-123. https://doi.org/10.1038/nrmicro3399.
19. Baquero F, Alvarez-Ortega C, Martinez JL. 2009. Ecology and evolution of antibiotic resistance. Environ Microbiol Rep 1:469-476. https://doi.org/10.1111/j.1758-2229.2009.00053.x.
20. Martínez JL, Baquero F, Andersson DI. 2011. Beyond serial passages: new methods for predicting the emergence of resistance to novel antibiotics. Curr Opin Pharmacol 11:439-445. https://doi.org/10.1016/j.coph.2011.07.005.
21. Fernández L, Hancock RE. 2012. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev 25: 661-681. https://doi.org/10.1128/CMR.00043-12.
22. Li XZ, Nikaido H. 2009. Efflux-mediated drug resistance in bacteria: an update. Drugs 69:1555-1623. https://doi.org/10.2165/11317030-000000000-00000.
23. Poole K. 2007. Efflux pumps as antimicrobial resistance mechanisms. Ann Med 39:162-176. https://doi.org/10.1080/07853890701195262.
24. Nikaido H. 2009. Multidrug resistance in bacteria. Annu Rev Biochem 78:119-146. https://doi.org/10.1146/annurev.biochem.78.082907.145923.
25. Saier MH, Jr, Paulsen IT, Sliwinski MK, Pao SS, Skurray RA, Nikaido H. 1998. Evolutionary origins of multidrug and drug-specific efflux pumps in bacteria. FASEB J 12:265-274.
26. Saier MH, Jr, Paulsen IT. 2001. Phylogeny of multidrug transporters. Semin Cell Dev Biol 12:205-213. https://doi.org/10.1006/scdb.2000.0246.
27. Paulsen IT, Chen J, Nelson KE, Saier MH, Jr. 2001. Comparative genomics of microbial drug efflux systems. J Mol Microbiol Biotechnol 3:145-150.
28. Alvarez-Ortega C, Olivares J, Martínez JL. 2013. RND multidrug efflux pumps: what are they good for? Front Microbiol 4:7. https://doi.org/10.3389/fmicb.2013.00007.
29. Martínez JL, Sánchez MB, Martinez-Solano L, Hernandez A, Garmendia L, Fajardo A, Alvarez-Ortega C. 2009. Functional role of bacterial multidrug efflux pumps in microbial natural ecosystems. FEMS Microbiol Rev 33: 430-449. https://doi.org/10.1111/j.1574-6976.2008.00157.x.
30. Lubelski J, Konings WN, Driessen AJ. 2007. Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria. Microbiol Mol Biol Rev 71:463-476. https://doi.org/10.1128/MMBR.00001-07.
31. Kuroda T, Tsuchiya T. 2009. Multidrug efflux transporters in the MATE family. Biochim Biophys Acta 1794:763-768. https://doi.org/10.1016/j.bbapap.2008.11.012.
32. Pao SS, Paulsen IT, Saier MH, Jr. 1998. Major facilitator superfamily. Microbiol Mol Biol Rev 62:1-34.
33. Chung YJ, Saier MH, Jr. 2001. SMR-type multidrug resistance pumps. Curr Opin Drug Discov Dev 4:237-245.
34. Nikaido H. 2011. Structure and mechanism of RND-type multidrug efflux pumps. Adv Enzymol Relat Areas Mol Biol 77:1-60. https://doi.org/10.1002/9780470920541.ch1.
35. Nikaido H, Takatsuka Y. 2009. Mechanisms of RND multidrug efflux pumps. Biochim Biophys Acta 1794:769-781. https://doi.org/10.1016/j.bbapap.2008.10.004.
36. Piddock LJ. 2006. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 19:382-402. https://doi.org/10.1128/CMR.19.2.382-402.2006.
37. Grkovic S, Brown MH, Skurray RA. 2001. Transcriptional regulation of multidrug efflux pumps in bacteria. Semin Cell Dev Biol 12:225-237. https://doi.org/10.1006/scdb.2000.0248.
38. Hernández A, Ruiz FM, Romero A, Martínez JL. 2011. The binding of triclosan to SmeT, the repressor of the multidrug efflux pump SmeDEF, induces antibiotic resistance in Stenotrophomonas maltophilia. PLoS Pathog 7:e1002103. https://doi.org/10.1371/journal.ppat.1002103.
39. Hernández A, Maté MJ, Sánchez-Díaz PC, Romero A, Rojo F, Martínez JL. 2009. Structural and functional analysis of SmeT, the repressor of the Stenotrophomonas maltophilia multidrug efflux pump SmeDEF. J Biol Chem 284:14428-14438. https://doi.org/10.1074/jbc.M809221200.
40. Poole K. 2005. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56:20-51. https://doi.org/10.1093/jac/dki171.
41. Jeannot K, Elsen S, Köhler T, Attree I, van Delden C, Plésiat P. 2008. Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. Antimicrob Agents Chemother 52:2455-2462. https://doi.org/10.1128/AAC.01107-07.
42. Linares JF, L>pez JA, Camafeita E, Albar JP, Rojo F, Martínez JL. 2005. Overexpression of the multidrug efflux pumps MexCD-OprJ and MexEFOprN is associated with a reduction of type III secretion in Pseudomonas aeruginosa. J Bacteriol 187:1384-1391. https://doi.org/10.1128/JB.187.4.1384-1391.2005.
43. Olivares J, Alvarez-Ortega C, Linares JF, Rojo F, Kóhler T, Martínez JL. 2012. Overproduction of the multidrug efflux pump MexEF-OprN does not impair Pseudomonas aeruginosa fitness in competition tests, but produces specific changes in bacterial regulatory networks. Environ Microbiol 14:1968-1981. https://doi.org/10.1111/j.1462-2920.2012.02727.x.
44. Cosson P, Zulianello L, Join-Lambert O, Faurisson F, Gebbie L, Benghezal M, Van Delden C, Curty LK, Köhler T. 2002. Pseudomonas aeruginosa virulence analyzed in a Dictyostelium discoideum host system. J Bacteriol 184:3027-3033. https://doi.org/10.1128/JB.184.11.3027-3033.2002.
45. Hirakata Y, Srikumar R, Poole K, Gotoh N, Suematsu T, Kohno S, Kamihira S, Hancock RE, Speert DP. 2002. Multidrug efflux systems play an important role in the invasiveness of Pseudomonas aeruginosa. J Exp Med 196:109-118. https://doi.org/10.1084/jem.20020005.
46. Warner DM, Folster JP, Shafer WM, Jerse AE. 2007. Regulation of the MtrC-MtrD-MtrE efflux-pump system modulates the in vivo fitness of Neisseria gonorrhoeae. J Infect Dis 196:1804-1812. https://doi.org/10.1086/522964.
47. Lertpiriyapong K, Gamazon ER, Feng Y, Park DS, Pang J, Botka G, Graffam ME, Ge Z, Fox JG. 2012. Campylobacter jejuni type VI secretion system: roles in adaptation to deoxycholic acid, host cell adherence, invasion, and in vivo colonization. PLoS One 7:e42842. https://doi.org/10.1371/journal.pone.0042842.
48. Arai H. 2011. Regulation and function of versatile aerobic and anaerobic respiratory metabolism in Pseudomonas aeruginosa. Front Microbiol 2:103. https://doi.org/10.3389/fmicb.2011.00103.
49. Arai H, Igarashi Y, Kodama T. 1991. Nitrite activates the transcription of the Pseudomonas aeruginosa nitrite reductase and cytochrome c-551 operon under anaerobic conditions. FEBS Lett 288:227-228. https://doi.org/10.1016/0014-5793(91)81040-F.
50. Arai H, Igarashi Y, Kodama T. 1991. Anaerobically induced expression of the nitrite reductase cytochrome c-551 operon from Pseudomonas aeruginosa. FEBS Lett 280:351-353. https://doi.org/10.1016/0014-5793(91)80329-2.
51. Tian ZX, Mac Aogáin M, O’Connor HF, Fargier E, Mooij MJ, Adams C, Wang YP, O’Gara F. 2009. MexT modulates virulence determinants in Pseudomonas aeruginosa independent of the MexEF-OprN efflux pump. Microb Pathog 47:237-241. https://doi.org/10.1016/j.micpath.2009.08.003.
52. Tian ZX, Fargier E, Mac Aogáin M, Adams C, Wang YP, O’Gara F. 2009. Transcriptome profiling defines a novel regulon modulated by the LysR-type transcriptional regulator MexT in Pseudomonas aeruginosa. Nucleic Acids Res 37:7546-7559. https://doi.org/10.1093/nar/gkp828.
53. Köhler T, Epp SF, Curty LK, Pechère JC. 1999. Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol 181:6300-6305.
54. Seeger MA, Diederichs K, Eicher T, Brandstätter L, Schiefner A, Verrey F, Pos KM. 2008. The AcrB efflux pump: conformational cycling and peristalsis lead to multidrug resistance. Curr Drug Targets 9:729-749. https://doi.org/10.2174/138945008785747789.
55. Zgurskaya HI, Nikaido H. 1999. Bypassing the periplasm: reconstitution of the AcrAB multidrug efflux pump of Escherichia coli. Proc Natl Acad Sci U S A 96:7190-7195. https://doi.org/10.1073/pnas.96.13.7190.
56. Picard M, Verchère A, Broutin I. 2012. Monitoring the active transport of efflux pumps after their reconstitution into proteoliposomes: caveats and keys. Anal Biochem 420:194-196. https://doi.org/10.1016/j.ab.2011.09.025.
57. Verchère A, Dezi M, Adrien V, Broutin I, Picard M. 2015. In vitro transport activity of the fully assembled MexAB-OprM efflux pump from Pseudomonas aeruginosa. Nat Commun 6:6890. https://doi.org/10.1038/ncomms7890.
58. Verchère A, Broutin I, Picard M. 2012. Photo-induced proton gradients for the in vitro investigation of bacterial efflux pumps. Sci Rep 2:306. https://doi.org/10.1038/srep00306.
59. White D, Drummond J, Fuqua C. 2011. The physiology and biochemistry of prokaryotes, 4th ed. Oxford University Press, Oxford, United Kingdom.
60. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC. 1997. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 23: 345-354. https://doi.org/10.1046/j.1365-2958.1997.2281594.x.
61. Arai H, Kodama T, Igarashi Y. 1997. Cascade regulation of the two CRP/FNR-related transcriptional regulators (ANR and DNR) and the denitrification enzymes in Pseudomonas aeruginosa. Mol Microbiol 25: 1141-1148. https://doi.org/10.1046/j.1365-2958.1997.5431906.x.
62. Comolli JC, Donohue TJ. 2004. Differences in two Pseudomonas aeruginosa cbb3 cytochrome oxidases. Mol Microbiol 51:1193-1203. https://doi.org/10.1046/j.1365-2958.2003.03904.x.
63. Evans K, Passador L, Srikumar R, Tsang E, Nezezon J, Poole K. 1998. Influence of the MexAB-OprM multidrug efflux system on quorum sensing in Pseudomonas aeruginosa. J Bacteriol 180:5443-5447.
64. ΔΔCT method. Methods 25:402-408. https://doi.org/10.1006/meth.2001.1262.
65. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.